Figure 3: The pre-(above) and post-treatment (below) CT imaging(A) and hybrid 18F-FDG PET imaging (B) in a breast cancer patient with non-response to neoadjuvant chemotherapy. After neoadjuvant chemotherapy, the radioactivity of 18F-FDG in breast cancer area was no significant difference, the tumor to non- tumor FDG radioactivity ratio was 2.76 (pre-treatment) and 2.68 (posttreatment) respectively.